Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 12/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 12/20 | 0.34 |
| ▸ | ITGB7 | P26010 | 10/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770836 | 0.91 | ITGB1 (0.35) | ITGB1ITGA4ITGB7ITGAVEGFR | |
| SCHEMBL2770073 | 0.88 | ITGB1 (0.36) | ITGB1ITGA4ITGB7ITGAVACLY | |
| SCHEMBL2770505 | 0.88 | ITGB1 (0.36) | ITGB1ITGA4ITGB7ITGAVBRAF | |
| SCHEMBL2771648 | 0.85 | ITGB1 (0.36) | ITGB1ITGA4ITGB7ITGAVEGFR | |
| SCHEMBL2770210 | 0.85 | ITGB1 (0.36) | ITGB1ITGA4ITGB7ITGAVEGFR | |
| SCHEMBL6038523 | 0.85 | ITGB1 (0.35) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL4206085 | 0.84 | ITGB1 (0.35) | ITGB1ITGA4ITGB7ACLYBRAF | |
| SCHEMBL5164317 | 0.84 | ITGB1 (0.38) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2770852 | 0.84 | ITGB1 (0.40) | ITGB1ITGA4ITGB7ITGAV | |
| Hydrochloric Acid SCHEMBL2769223 | 0.84 | ITGB1 (0.38) | ITGB1ITGA4ITGB7ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507533-B1 | HETEROARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA-4 INTEGRINS | ELAN PHARM INC (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20060004019-A1 | Steroid sparing agents and methods of using same | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2006-01-05 | — | — | US | disclosed |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004019-A1 | Steroid sparing agents and methods of using same | IL5, FCER2, CD40 | ITGB1 305/4885ITGA4 298/4885ITGB7 485/4885 |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | ITGB1 8/4885ITGA4 3/4885ITGB7 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.